Published in J Urol on June 01, 2003
Impact of a multidisciplinary continuous quality improvement program on the positive surgical margin rate after laparoscopic radical prostatectomy. Eur Urol (2006) 1.50
Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database. Prostate Cancer Prostatic Dis (2008) 0.87
Preoperative factors predictive of posterolateral extracapsular extension after radical prostatectomy. Korean J Urol (2013) 0.82
Optimizing radical prostatectomy for the early recovery of urinary continence. Nat Rev Urol (2012) 0.81
Laparoscopic radical prostatectomy: the learning curve of a low volume surgeon. ScientificWorldJournal (2013) 0.80
Transition from open to robotic-assisted radical prostatectomy is associated with a reduction of positive surgical margins amongst private-practice-based urologists. J Robot Surg (2007) 0.80
Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression? Urol Ann (2010) 0.79
Bladder neck sparing in radical prostatectomy. Indian J Urol (2013) 0.76
Complications, urinary continence, and oncologic outcomes of laparoscopic radical prostatectomy: single-surgeon experience for the first 100 cases. Prostate Cancer (2011) 0.75
Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. Prostate Cancer Prostatic Dis (2016) 0.75
Development of a novel classification system for anatomical variants of the puboprostatic ligaments with expert validation. Can Urol Assoc J (2014) 0.75
Da Vinci prostatectomy: athermal nerve sparing and effect of the technique on erectile recovery and negative margins. J Robot Surg (2007) 0.75
The Null Effect of Bladder Neck Size on Incontinence Outcomes After Radical Prostatectomy. J Urol (2017) 0.75
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review. Urology (2010) 2.19
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 1.63
Modified supine percutaneous nephrolithotomy for large kidney and ureteral stones: technique and results. Eur Urol (2011) 1.58
External validation of the updated partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys (2008) 1.58
The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54
Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol (2013) 1.51
The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol (2011) 1.50
Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate (2011) 1.49
Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42
International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol (2015) 1.41
Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther (2002) 1.40
Surgical management of BPH in patients on oral anticoagulation: transurethral bipolar plasma vaporization in saline versus transurethral monopolar resection of the prostate. Can J Urol (2011) 1.38
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol (2010) 1.30
Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology (2003) 1.28
Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27
Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod (2003) 1.25
Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res (2007) 1.23
Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int (2012) 1.18
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology (2003) 1.18
Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. BJU Int (2010) 1.18
Urine biomarkers in prostate cancer. Nat Rev Urol (2010) 1.17
Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int (2007) 1.16
Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol (2004) 1.15
The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13
Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol (2003) 1.13
Comparison of early oncologic results of laparoscopic radical prostatectomy by extraperitoneal versus transperitoneal approach. Eur Urol (2004) 1.12
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int (2008) 1.11
Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer (2007) 1.11
Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients. BJU Int (2010) 1.10
SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology (2012) 1.10
Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology (2012) 1.09
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol (2007) 1.08
The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int (2011) 1.08
Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol (2012) 1.07